Literature DB >> 25900737

Camptocormia as presenting manifestation of a spectrum of myopathic disorders.

Partha S Ghosh1,2, Margherita Milone2.   

Abstract

INTRODUCTION: Camptocormia is the involuntary flexion of the thoracolumbar spine leading to an abnormal posture.
METHODS: We retrospectively identified patients with myopathy who manifested with camptocormia and were seen in our neuromuscular clinic. The diagnosis of myopathy was based on myopathic electromyographic changes, often accompanied by 1 or more of the following: elevated creatine kinase (CK); myopathic histopathological findings; and genetic confirmation.
RESULTS: Fifty-two patients were identified; 35 had symptoms limited to camptocormia, but were found to have additional weakness of facial (8 patients), neck (11 patients), and limb muscles (17 patients). CK values were normal or mildly to moderately elevated. MRI/CT of the spine showed paraspinal muscle atrophy and fat replacement. Facioscapulohumeral muscular dystrophy and sporadic inclusion body myositis were the most commonly identified myopathies in this cohort.
CONCLUSIONS: Despite the difficulty in characterizing the myopathy in patients with camptocormia, a definitive diagnosis was possible in 54% of cases. The pattern of associated extra-axial weakness may provide clues to the diagnosis.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  axial myopathy; bent spine syndrome; camptocormia; muscle weakness; myopathy

Mesh:

Substances:

Year:  2015        PMID: 25900737     DOI: 10.1002/mus.24689

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  7 in total

Review 1.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 2.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

3.  Camptocormia as the presenting symptom in sporadic late onset nemaline myopathy: a case report.

Authors:  Matthias Türk; Armin M Nagel; Frank Roemer; Ursula Schlötzer-Schrehardt; Christian T Thiel; Martin Winterholler; Rolf Schröder
Journal:  BMC Musculoskelet Disord       Date:  2019-11-20       Impact factor: 2.362

4.  Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.

Authors:  Giulia Ricci; Fabiano Mele; Monica Govi; Lucia Ruggiero; Francesco Sera; Liliana Vercelli; Cinzia Bettio; Lucio Santoro; Tiziana Mongini; Luisa Villa; Maurizio Moggio; Massimiliano Filosto; Marina Scarlato; Stefano C Previtali; Silvia Maria Tripodi; Elena Pegoraro; Roberta Telese; Antonio Di Muzio; Carmelo Rodolico; Elisabetta Bucci; Giovanni Antonini; Maria Grazia D'Angelo; Angela Berardinelli; Lorenzo Maggi; Rachele Piras; Maria Antonietta Maioli; Gabriele Siciliano; Giuliano Tomelleri; Corrado Angelini; Rossella Tupler
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

Review 5.  Camptocormia: Etiology, diagnosis, and treatment response.

Authors:  Farwa Ali; Joseph Y Matsumoto; Anhar Hassan
Journal:  Neurol Clin Pract       Date:  2018-06

6.  A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes.

Authors:  Giulia Ricci; Lucia Ruggiero; Liliana Vercelli; Francesco Sera; Ana Nikolic; Monica Govi; Fabiano Mele; Jessica Daolio; Corrado Angelini; Giovanni Antonini; Angela Berardinelli; Elisabetta Bucci; Michelangelo Cao; Maria Chiara D'Amico; Grazia D'Angelo; Antonio Di Muzio; Massimiliano Filosto; Lorenzo Maggi; Maurizio Moggio; Tiziana Mongini; Lucia Morandi; Elena Pegoraro; Carmelo Rodolico; Lucio Santoro; Gabriele Siciliano; Giuliano Tomelleri; Luisa Villa; Rossella Tupler
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

Review 7.  Pathophysiological Concepts and Treatment of Camptocormia.

Authors:  N G Margraf; A Wrede; G Deuschl; W J Schulz-Schaeffer
Journal:  J Parkinsons Dis       Date:  2016-06-16       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.